Helsinn-Kyowa ink license & distribution agreement for VALCHLOR®

Helsinn-Kyowa ink license & distribution agreement for VALCHLOR®

Published: Just now By Saipriya Iyer

Helsinn Group, a leading supportive cancer care company, has recently inked an exclusive license & distribution agreement for VALCHLOR® gel 0.016% in China. VALCHLOR® (mechlorethamine) gel has been used as a topical treatment of....

South Korea to procure more COVID-19 vaccine as cases spike

As the entire world is preparing for the second wave of coronavirus outbreak, it seems that nations worldwide are focusing on strengthening their vaccine supplies to tackle the pandemic. As per the latest news, a significant number of COVID....

South African retailers go local to secure clothing supply chain

Several South African retailers, which also includes the likes of Woolworths Holdings Ltd. and The Foschini Group Ltd., are reportedly increasing their investment in the country’s local clothing companies, both in an attempt to reduce....

Consumer electronics retailer Best Buy to shut operations in Mexico

Best Buy, a leading American consumer electronics retailer, has reportedly decided to shut all its operations in Mexico. The move was announced after the firm’s Chief Executive Officer, Corie Barry revealed the firm’s decision t....

13 countries in Africa unite to find a potential COVID-19 treatment

Thirteen African nations have joined hands with researchers across the world to rollout the largest clinical study of potential coronavirus treatments on the African continent. The trial, dubbed the Anticov study, involves contributions fr....

Cleveland Clinic & Anixa submit IND for their breast cancer vaccine

Anixa Biosciences, Inc., a renowned biotechnology firm primarily focused on the prevention and treatment of cancer as well as other infectious diseases, has reportedly announced that a new IND application for the company’s innovative ....

Sydney University researchers to get $1.12 million for vaccine testing

Researchers at the University of Sydney have reportedly been rewarded over $1.12 million as funding from the IMCRC (Innovative Manufacturing CRC) to conduct independent clinical research tests to assess the efficacy of needle-free vaccinati....

Industry Updates